Solasia, a Japan-headquartered company, has received a nod from SFDA to conduct clinical trials in China for Sancuso. Sancuso is a transdermal patch product for the treatment of
chemotherapy-induced
nausea and vomiting. Solasia in-licensed rights to
Sancuso for Southeast Asia in 2008 from, ProStrakan - the UK subsidiary of Kyowa Hakko Kirin. Kyowa acquired Prostrakan in April 2011.
Solasia will begin a trial of the product immediately and expects to
file a New Drug Application in China during Q4 of 2013.